South Africa’s first ethically approved clinical trials of cannabis have begun in Johannesburg with the goal of determining whether cannabis can replace opioids for pain management, according to June 21. press release. Cannabis is showing more and more potential to reduce or replace opioids for certain types of pain management.
The researchers will monitor 1,000 participants who have been taking opioids for pain management for at least three months and are willing to switch to cannabis as an alternative. Two of the chemicals currently in use are Tallyman and Exodus – sourced from Labat’s Sweetwaters Aquaponics SAHPRA licensed facility in the Eastern Cape. Aquaponics is a cultivation technique It is believed that it allows for more benefits. The third strain to be introduced soon, the 9lb Hummer, will be chosen next – due to its high level of THC and CBG, and being rich in beta-carophylline and myrcene.
“We are currently recruiting patients, and collecting data for all questionnaires and feedback from patients for the live study,” said Dr. Gallo. “It was rather slow. However, more options were offered in the live study as suggested by the patients in the pilot study. The experimental results of the study were very promising, showing that 98% of patients had some form of pain relief from cannabis.”
Researchers were able to wean patients off opioid therapy. The flower contained a high amount of THC, 15-25 mg of THC, with 0.5 mg of CBD. The oil’s balanced formulation (1:1 ratio) contains 15-20 mg THC / 15-20 mg CBD. In the experimental group, patients under 55 years of age preferred to smoke the flower, while patients over 55 years of age preferred the oil. Patients smoking cannabis felt relief almost immediately, while the oil took time.
Dr. Peter Grinspoon is a medical cannabis specialist at Massachusetts General Hospital and an instructor at Harvard Medical School, as well as the son of a psychiatrist and longtime cannabis attorney. Lester Grinspoon. Could you Watch him discuss America’s opioid crisis on HarvardX or similar topics on TEDx.
“First of all, I think cannabis is really good for mild to moderate pain,” says Dr. Grinspoon. High Times. “I no I think it works for severe pain. So I think it depends a little bit on the patient’s condition and how severe their pain is, and not just a matter of taking cannabis and opium or not taking cannabis and opioids. Together, they work very well. Synergistically, they act together on some of the same receptors.”
Grinspoon added that people who turn to this alternative can achieve a better quality of life, and cannabis is generally safer than opioids. “But I think else People who are likely to achieve a dose reduction, which would also be a significant reduction in harm [benefit]. So again, it’s not really binary, like an opiate that’s emitted from opioids or not from opioids.”
There is evidence to show that other people have reduced opioid use with the help of cannabis – which makes it very stupid to test people on cannabis opioids because it might help them.
“There is no reason for a pain specialist to consider him an enemy,” he said.
“We don’t really know how effective opioids are,” Dr. Grinspoon added, since there are people with withdrawal symptoms who struggle with pain that’s hard to separate from chronic pain. But then again, there are people with severe pain such as phantom limb pain who absolutely need opioids.
“Either they’re nonsteroidal opioids, you know, like your Advil, your Motrin, and those aren’t safe either,” Dr. Grinspoon says.
This stuff is really dangerous, and it can cause heart attacks, stomach ulcers, and a lot of kidney damage. So the question is, what is the least harmful drug to use for chronic pain? There is no free lunch. All medications have side effects, and cannabis certainly has side effects, but I always ask myself, “What is the least dangerous thing to use and often?”
He said cannabis is definitely safer than opioids, and he wonders if in some cases it’s safer than a non-steroid.
Meanwhile, research showing the true potential of cannabis for pain management is growing. Dr. Gallo’s team of researchers in South Africa renewed this study for another year.